Native human interferon beta data

The Geneva, Switzerland, company reported interim results at six months showing a 67 percent reduction in the number of active lesions on T1 and T2(A) MRI scans in an open-label, multicenter, randomized, controlled trial in Spain.

As presented at the meeting of the European Committee for Treatment and Research in Multiple Sclerosis in Athens, 59 percent of patients with relapsing-remitting MS treated with interferon beta remained free of exacerbations, compared to 31 percent of controls. Patients had EDSS disability scores of 0 to 5. ...